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Abstract
We tested the influence of IFNg on proteasome activity in parental Hep G2 cells that do not metabolize ethanol, as well as in
recombinant Hep G2-derived cells that express either or both alcohol dehydrogenase (ADH) and cytochrome P4502E1 (CYP2E1). IFNg
treatment increased proteasome activity in VL-17A (ADHþ, CYP2E1þ) and E-47 (CYP2E1þ) cells, but not in Hep G2, VI-R2 (parental
cells with empty vectors) or in VA-13 (ADHþ) cells. Proteasome activation by IFNg correlated positively with the level of CYP2E1
activity. Treatment of VL-17A cells with agents that inhibit CYP2E1 or the inducible nitric oxide synthase (iNOS) or that prevent the
formation of peroxynitrite also blocked proteasome activation by IFNg, indicating that the proteasome may be directly activated by
products of CYP2E1 and iNOS catalysis. While IFNg treatment increased proteasome activity, it also decreased CYP2E1 activity. Both
effects were mediated via the Janus kinase-signal transducer and activator of transcription 1 (JAK-STAT1) pathway, as both were blocked
by the JAK2 inhibitor, tyrphostin AG 490. Ethanol treatment of VL-17A cells also caused a similar blockage of these same IFNg-mediated
effects, by inhibiting STAT1 phosphorylation. This inhibition was largely due to ethanol metabolism, as 4-methylpyrazole, an ethanol
metabolism inhibitor, restored IFNg-mediated STAT1 phosphorylation in ethanol-treated cells. Our results lead us to propose that IFNg
initiates signal transduction, which alters the activities of CYP2E1 and iNOS, thereby producing reactive oxygen species. One of these
oxidants, possibly peroxynitrite, may be directly involved in proteasome activation. Ethanol metabolism by VL-17A cells suppresses
IFNg-mediated induction of proteasome activity, in part, by preventing STAT1 phosphorylation.
# 2003 Elsevier Inc. All rights reserved.
Keywords: Proteasome; Signal transduction; STAT1; Ethanol metabolism; Interferon gamma

1. Introduction
The proteasome is a large proteolytic particle that contains multiple catalytic activities for protein degradation.
The proteasome participates in the regulation of normal
physiological processes in cells, by degrading short-lived
*
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regulatory proteins that have roles in vital cellular functions including proliferation and apoptosis, as well as
degrading long-lived constitutive enzymes. The proteasome also has an important role in cellular defense by
degrading damaged, potentially cytotoxic proteins [1–4].
Thus, the proteasome is vital for many important cell
functions [5,6]. The enzyme particle is also involved in
antigen presentation [7]. The specific subunits of the
immunoproteasome, cleave proteins to distinct peptides,
which form complexes with major histocompatibility complex (MHC) class I molecules on the cell surface. These
complexes can be recognized by cytotoxic T-lymphocytes
(CTLs) that eliminate target cells with foreign peptide
repertoires [8]. Any MHC class Iþ host cell, including
the hepatocyte, may be targeted by CTLs [9,10].

698

N.A. Osna et al. / Biochemical Pharmacology 66 (2003) 697–710

The liver is the primary site of ethanol oxidation, and this
organ sustains significant damage from chronic ethanol
consumption [11]. In vitro studies using Hep G2-derived
cells have demonstrated that ethanol-induced cytotoxicity
depends on the levels of expression of the ethanol-metabolizing enzymes, CYP2E1 or ADH [12,13] and therefore,
on the levels of ethanol oxidation. There is evidence that
metabolites generated from ethanol oxidation can exert
inhibitory effects on a number of cellular pathways including the activity of the proteasome. In hepatocytes of patients
with alcohol-induced liver disease, Mallory bodies are
typical histological hallmarks [14]. These are believed to
form as a result of compromised proteasome function or
even proteasome depletion [15]. Ethanol consumption can
cause reduced hepatic proteasome activity. This effect is
associated with high blood ethanol levels in vivo when
ethanol is administered by continuous intragastric feeding,
which, also results in increased hepatic lipid peroxidation
(oxidative stress) [16,17]. Impaired proteasome function
appears to result from ethanol metabolism [18]. Pro-inflammatory cytokines, including IFNg, are natural modulators
of proteasome activity [19]. IFNg acts on a cell by binding
to surface IFNg receptors, which initiate the transduction of
signals to nuclear genes via the JAK-STAT1 pathway. This
occurs by phosphorylation of STAT1, which is then translocated to the nucleus and binds to DNA, initiating downstream effects, which include the modulation of proteasome
function in antigen-presenting cells, such as macrophages
and dendritic cells [20,21]. However, the effect of IFNg on
proteasome activity in liver cells has not been characterized.
The aim of this work was to study the response of the
proteasome to IFNg and the transduction of IFNg signals in
recombinant Hep G2 cells incubated in the presence or
absence of ethanol. We tested the influence of IFNg on
proteasome chymotrypsin-like activity in parental Hep G2
cells that do not metabolize ethanol, as well as in recombinant Hep G2-derived cells that express either or both
ADH and CYP2E1. We also determined whether ethanol
itself or the products of its metabolism altered the responsiveness of the proteasome to IFNg. We found that IFNg
treatment enhanced proteasome activity via the JAKSTAT1 pathway and that this enhancement occurred only
in CYP2E1-expressing cells. Here, we provide evidence
that this effect may be mediated by peroxynitrite. We
further show that prior exposure of cells to ethanol prevented the IFNg-induced increase in proteasome activity
by blocking STAT1 phosphorylation. Portions of this work
have been described in recent abstracts [22,23].

2. Materials and methods
2.1. Reagents and media
High glucose Dulbecco’s modified Eagle medium
(DMEM) and fetal bovine serum (FBS) were purchased

from Invitrogen. The membrane-permeable flourogenic proteasome substrate, methoxysuccinyl-phe-leu-phe7-amido-4-trifluoromethyl coumarin (FLF-AFC) was
obtained from Enzyme Systems Products. Human recombinant IFNg was from PeproTech, Inc. Anti-IFNgRa was
from PharMingen. The antibody preparations to phosphorylated signal transducer and activator of transcription
1 (pSTAT1) and STAT1 were from Cell Signaling and from
Santa Cruz Biotechnology, Inc., respectively. Diallyl sulfide (DAS), tyrphostin AG 490, and succinyl-Leu-Leu-ValTyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) were
purchased from Sigma. N,o-Nitro-L-arginine methyl
ester (L-NAME), epigallocatechin gallate (EGCG), and
6,10,15,20 tetrakis(4-sulfonatophenyl) porphyrinato iron
(III) chloride (FeTPPS) were from Calbiochem. All other
chemicals used were analytical grade quality.
2.2. Cell lines
All cell lines were derived from the human hepatoblastoma cell line Hep G2, which were obtained from the
American Type Culture Collection. Cells expressing both
ADH and CYP2E1 were developed by transfecting VA-13
(ADHþ) cells with the expression vector pIV-G2. This
vector contains the coding region of the human cytochrome
P4502E1 gene. The coding region was kindly provided by
Dr. Frank Gonzalez (National Cancer Institute). VA-13
cells were transfected using Lipo TAXI (Invitrogen Corp.)
as described by the manufacturer. Recombinant cells were
selected in culture medium containing G418 and zeocin,
each at 400 mg/mL. Clones were isolated, and clonal cell
lines established. Clones were expanded and screened for
ADH and CYP2E1 activity. One of the resulting clones,
designated VL-17A, was used in the present study. These
cells were phenotypically identical to VA-13 cells [12] in
their ability to metabolize ethanol and generate acetaldehyde, but they also express CYP2E1 at levels that are
comparable to those of rat hepatocytes [24].1 As a control
cell line, Hep G2 cells were transfected with both empty
vectors, pcDNA3.1 and pcDNA3.1/Zeo(þ) (Invitrogen).
These transfected cells were designated VI-R2 cells.
CYP2E1-expressing E-47 cells were the kind gift of Dr.
A. Cederbaum (Mount Sinai School of Medicine).
2.3. Alcohol dehydrogenase (ADH) activity
Cells were washed with phosphate-buffered saline (PBS)
and then detached from the plastic by treating with trypsin.
Dislodged cells were resuspended in PBS and lysed by
sonication. Each lysate was centrifuged at low speed to
remove cell debris, and the supernatant was centrifuged for
1 hr at 105,000 g to sediment the microsome fraction. The
supernatant (cytosol) was removed and supplemented with
glycerol to a final concentration of 20% (v/v). ADH activity
1
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in the cytosolic fraction was measured as originally described by Crow et al. [25] and modified by Clemens et al.
[26] and normalized for protein concentration. One ADH
enzyme unit catalyzed the formation of 1 nmol of NADH
(nicotinamide adenine dinucleotide, reduced form) per hour.
Specific activity is expressed as units per mg protein.
2.4. CYP2E1 catalytic activity
The microsome pellet derived from the 105,000 g centrifugation was re-suspended in 250 mL PBS containing
20% glycerol. CYP2E1 activity was measured by hydroxylation of p-nitrophenol, as described originally by Koop
[27] and modified by Chen et al. [28]. In this micro-assay,
the mixture had a final volume of 100 mL and was incubated for 1 hr. Formation of 4-nitrocatechol (4-NC), the
reaction product, was measured by absorbance at 515 nm.
This was compared to the absorbance obtained using
known quantities of 4-nitrocatechol (4-NC). One CYP2E1
enzyme unit catalyzed the formation of 1 nmol 4-NC/hr.
Specific activity is expressed as units per mg protein.
Protein concentration was measured by the dye binding
technique of Bradford [29] using reagents from Bio Rad.
2.5. In situ proteasome assay
The chymotrypsin-like activity of the proteasome was
measured by FLF-AFC hydrolysis, which was determined
by a modification of the method described previously [30].
Briefly, cells were plated into 24-well plates at a density of
1  105 cells/well in DMEM supplemented with appropriate antibiotics and 10% FBS. After 24 hr of incubation,
the medium was replaced with DMEM containing 3% FBS
and 25 mM HEPES. For experiments using ethanol, plates
were sealed with adhesive sealing films for micro-plates
(ThermalSealTM, Excel Scientific) to prevent ethanol evaporation. After 72 hr incubation at 378, the medium was
replaced with serum-free DMEM containing 13 mM FLFAFC. Fluorescence of AFC was measured every 2 hr on a
Fluorolite 1000 plate reader (Dynex Technologies) using
excitation and emission filter settings of 390 and 530 nm,
respectively. After the last reading, the attached cells were
lysed by direct sonication of each well, and samples were
taken for the fluorometric measurement of DNA [31],
which was used for normalization. Data are expressed
as nmole AFC/mg DNA. Nanomoles of AFC were calculated on the basis of an AFC standard curve. To determine
the specificity of proteasome activity with FLF-AFC, cells
were treated with 10 mM lactacystin, a specific proteasome
inhibitor, which caused a 70% decline in the rate of FLFAFC hydrolysis (data not shown).
2.6. In vitro proteasome assay
For in vitro measurements of chymotrypsin-like activity
of the proteasome, cells were lysed by sonication in PBS.

699

Suc-LLVY-AMC hydrolysis using cytosolic fractions of
the lysates was tested as described by Donohue et al. [16].
2.7. Exposure of cells to IFNg
In most cases, cells were exposed to IFNg (10 ng/mL),
for 24 hr. In some dose–response and kinetic experiments,
the concentration of IFNg varied from 2 to 50 ng/mL, and
the duration of treatment varied between 0 and 24 hr.
2.8. Detection of interferon gamma receptor alpha
(IFNgRa)
To determine the relative levels of IFNgRa, cells were
plated onto 6-well plates at 1  106 cells/well in DMEM
supplemented with 3% FBS, 25 mM HEPES and ethanol
(0 or 100 mM). After incubation for 72 hr, cells were
washed with PBS and detached from the plate using
Cellstripper (Cellgro), centrifuged, washed and suspended
in blocking buffer (PBS containing 0.1% sodium azide and
3% FBS) for 15 min to prevent non-specific binding of
protein. Cells (1  106 /tube) were incubated in 100 mL for
30 min on ice with 1 mg of phycoerythrin-conjugated antihuman IFNgRa (PharMingen) and then washed twice in
cold PBS. As an isotype control, anti-human IgG-PE
antibody (PharMingen), was used. The cells were analyzed
with a FACSCAN flow cytometer (Becton Dickinson) to
detect bound antibody.
2.9. Detection of STAT1 and phospho-STAT1
Cells were plated onto 6-well plates using DMEM with
10% FBS. After overnight attachment at 378, the medium
was changed to serum-free DMEM with or without
100 mM ethanol, and cells were incubated for 72 hr. Cells
were treated or not with IFNg (10 ng/mL), for 1, 5 or 24 hr.
Then, cells were lysed by freezing and thawing using
0.5 mL of lysis buffer (40 mM Tris–HCl (pH 7.4),
1 mM EDTA, 10 mM sodium pyrophosphate, 2 mM
sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 100 mM sodium fluoride, 1% Triton X-100, 2 mg aprotinin/mL). A portion of each lysate (30 mg protein/well)
was subjected to SDS–PAGE on 12% gels. Proteins were
electrophoretically transferred onto nitrocellulose membranes. Membranes were blocked with 5% bovine serum
albumin (BSA) for 1 hr at room temperature and
then incubated overnight at 48 with anti-phospho-STAT1
(pSTAT1), diluted 1:1000. The membranes were extensively washed with Tris-buffered saline containing 0.1%
Tween 20 (TBS-T), exposed to 5000-fold diluted peroxidase-conjugated, goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc.), washed and visualized by
enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech). The same membranes were then stripped for
30 min at 508 in 62.5 mM Tris–HCl pH 6.7, 100 mM
2-mecaptoethanol, 2% sodium dodecyl sulfate. They were
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re-blocked in 5% dry non-fat milk–TBS-T overnight at 48
and exposed to anti-STAT1 (1:1000) antibodies for 1 hr at
room temperature. Subsequently, the membranes were
incubated with peroxidase-conjugated secondary antibodies (1:2000) and visualized by ECL. The bands were
quantified by densitometry, and the pSTAT1/STAT1 densitometric ratio was calculated.

2.10. Statistical analyses
Data are expressed as mean values  standard deviation.
Because the analyzed parameters had a normal distribution,
comparisons for significance were determined by Student’s
t-test between two groups or by one-way ANOVA, using a
Tukey post-test for multiple comparisons. For correlations,

Fig. 1. Effects of IFNg on the chymotrypsin-like activity of the proteasome in ethanol-metabolizing VL-17A and ethanol non-metabolizing Hep G2 and VIR2 cells. Cells were plated onto 24-well plates and then exposed to IFNg or left untreated. (A and B) Proteasome activity was assayed in situ after various
times of exposure to IFNg (10 ng/mL) in VL-17A cells or Hep G2 cells. (C and D) Proteasome activity after 24 hr exposure to various doses of IFNg in VL17A or Hep G2 cells. (E) Proteasome activity after 24 hr of treatment with IFNg (10 ng/mL) in VL-17A cells and VI-R2 cells. Data presented are mean values
(SD) of proteasome activity (nmol AFC/mg DNA) that were calculated from four independent experiments (quadruplicate measurements in each
experiment). Asterisk indicates a significant difference at P < 0:05 between IFNg-treated and -untreated cells.

N.A. Osna et al. / Biochemical Pharmacology 66 (2003) 697–710

Pearson’s coefficient of correlation was used. A probability
value of 0.05 or less was considered significant.

3. Results
To determine whether IFNg affects the activity of the
proteasome, we treated VL-17A and VI-R2 and/or Hep G2
cells with various doses of IFNg (2–50 ng/mL) for 1–24 hr.
Chymotrypsin-like activity of the proteasome was subsequently tested in situ by FLF-AFC hydrolysis. Exposure to
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IFNg increased FLF-AFC hydrolysis by 20–50% in
VL-17A cells compared with their untreated controls. This
increase was first detected after 4 hr of treatment with IFNg
and remained elevated after 24 hr (Fig. 1A). Proteasome
activity in cell lysates or the cytosolic fractions of VL-17A
cells assayed in vitro with Suc-LLVY-AMC was increased
up to 40% after treatment with IFNg (not shown). However, proteasome activity in VI-R2 and Hep G2, both
ethanol non-metabolizing cells, did not increase in
response to IFNg treatment regardless of IFNg dose and
time of treatment (Fig. 1B, D and E).

Fig. 2. Effects of ethanol treatment on proteasome activity after IFNg treatment of VL-17A and VI-R2 cells. Cells were exposed to the indicated
concentrations. After 48 hr of ethanol exposure, cells were treated or not with IFNg for 24 hr. Data represent mean values (SD) of six independent
experiments (quadruplicate measurements in each experiment), after 6 hr of incubation with FLF-AFC. Asterisk indicates significant difference between the
proteasome activity in the presence (dark bars) or absence of IFNg (open bars). Double asterisks indicate significant difference between ethanol-untreated
cells (without exposure to IFNg) and ethanol-treated cells.
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We examined whether ethanol influenced the activation
of the proteasome by IFNg. VL-17A and VI-R2 cells were
each treated with 0, 25, 50 and 100 mM ethanol for 72 hr
and then exposed to IFNg. Ethanol alone, at all concentrations, had no effect on proteasome activity in Hep G2 cells
(not shown), or in VI-R2 cells (data shown in Fig. 2, panel
B). However, 100 mM ethanol treatment caused a 30–40%
decrease in proteasome chymotrypsin-like activity in
VL-17A cells compared with their untreated controls.
Additionally, in VL-17A cells, ethanol, at even lower
concentrations (25 and 50 mM) that, by themselves, did
not significantly affect FLF-AFC hydrolysis, prevented
proteasome activation by IFNg (Fig. 2).
The unresponsiveness of Hep G2 and VI-R2 cells to
IFNg (Fig 1B, D and E) was not due to reduced levels or the
absence of IFNg receptors on these cells. Flow cytometric
analyses revealed that both VI-R2 and VL-17A cells had
comparable numbers of IFNgR-positive cells. Non-specific
staining with isotype-specific antibodies occurred in less
than 0.5% of cells. Furthermore, there was no indication
that treatment with 100 mM ethanol for 72 hr reduced
IFNgR levels in either cell type (Fig. 3).
Because proteasome activity was enhanced by IFNg in
VL-17A but not in VI-R2 or Hep G2 cells, we tested the
possibility that ADH and/or CYP2E1 expression may be
involved in IFNg-induced activation of the proteasome. We
treated ADH-expressing VA-13 cells and CYP2E1-expressing E-47 cells with IFNg for 24 hr. IFNg treatment
enhanced proteasome activity in E-47 cells by 20%
(P ¼ 0:05), but it caused no change in proteasome activity
in VA-13 cells (Fig. 4), indicating that the IFNg-mediated
elevation of proteasome activity was related to CYP2E1,
but not to ADH expression.
CYP2E1 activity in VL-17A cells was not constant in all
experiments. Enzyme activity varied as much as 2-fold
between passages. We noted that the magnitude of proteasome activation by IFNg was positively associated with the
basal CYP2E1 activity of VL-17A cells before treatment
with the cytokine. Statistical determination of such a
correlation indeed showed that VL-17A cells with higher
CYP2E1 activity had a greater degree of proteasome
activation with IFNg than those with lower CYP2E1
activity (Pearson r ¼ 0:9389, P ¼ 0:0055). Conversely,
pretreatment of cells with 10 mM diallyl sulfide (DAS),
an inhibitor of CYP2E1 catalytic activity [32], prevented
proteasome activation by IFNg (Fig. 5). These data indicate that a product of CYP2E1 catalysis may have a role in
proteasome activation following treatment with IFNg.
IFNg also increases iNOS activity, which results in the
increased production of nitric oxide (NO) [33]. To determine the contribution of IFNg-mediated NO formation to
proteasome activation, we treated VL-17A cells with IFNg
in the presence of the iNOS inhibitors, L-NAME (300 mM)
and EGCG (200 mM) for 24 hr. Both agents blocked
proteasome activation by IFNg (Fig. 6A and B). These
latter data indicated that NO, in addition to the product

Fig. 3. Flow cytometric analysis of IFNg receptor (IFNgRa) in ethanoltreated and -untreated VL-17A and VI-R2 cells. Cells were treated or not
with 100 mM ethanol for 72 hr and then prepared for flow cytometric
analysis as described in Section 2. The cells were analyzed by flow
cytometry (three independent experiments). The data show a representative
scan from one experiment. Panel A: VI-R2 cells, panel B: VL-17A cells;
bold line is untreated cells, dashed line is ethanol-treated cells.

derived from CYP2E1 catalysis, participated in IFNgelicited proteasome activation. To test the possibility that
peroxyntrite may be the responsible agent, we treated
VL-17A cells with IFNg and the peroxynitrite scavenger,
FeTPPS (10 mM), which converts peroxynitrite to NO [34].
This compound also prevented proteasome activation by
IFNg (Fig. 6C).
In accordance with previous findings [35], IFNg treatment of VL-17A cells for 24 hr decreased CYP2E1 activity
by 50%. However, exposure of these cells to 100 mM
ethanol for 72 hr enhanced CYP2E1 activity up to 5-fold.
This effect was slightly, but not significantly attenuated by
IFNg (Fig. 7).
To determine whether CYP2E1 and proteasome activities are regulated by IFNg via the JAK-STAT pathway, we
exposed VL-17A cells to IFNg in the presence and absence
of the selective JAK2 phosphorylation inhibitor, tyrphostin
AG 490. This treatment prevented the enhancement of

N.A. Osna et al. / Biochemical Pharmacology 66 (2003) 697–710

703

Fig. 4. Effects of IFNg on proteasome activity in VA-13 and E-47 cells. Cells were exposed or not to IFNg (10 ng/mL) for 24 hr. The data represent mean
values (SD) of three independent experiments (quadruplicate measurements in each), obtained after 6 hr of incubation with FLF-AFC. Asterisk indicates
significant difference between IFNg-treated (dark bars) and untreated cells (open bars) at P < 0:05.

proteasome activity as well as the decrease of CYP2E1
activity (Fig. 8), indicating that the JAK-STAT pathway is
involved in both these processes.
We further tested the effects of ethanol on the transduction of IFNg signal via the JAK-STAT1 pathway using
ethanol-metabolizing VL-17A cells and non-metabolizing
Hep G2 cells. During the final 24 hr interval of a 72 hr

ethanol exposure, cells were treated or not with IFNg
(10 ng/mL), for 0, 1, 5 and 24 hr. Both phosphorylated
STAT1 (pSTAT1) and total STAT1 were determined in cell
lysates by Western blot. As shown in Fig. 9, ethanol
treatment decreased the pSTAT1/STAT1 ratio in Hep G2
cells by 1.5–2-fold compared with untreated cells after 1 hr
of IFNg exposure. By comparison, the pSTAT1/STAT1

Fig. 5. The effects of diallyl sulfide (DAS) on IFNg-activation of proteasome activity in VL-17A cells. VL-17A cells were treated or not with 10 mM DAS, for
24 hr. The cells were then treated or not with IFNg (10 ng/mL), in the presence or absence of DAS, for the next 24 hr. The data represent mean values (SD) of
quadruplicate measurements from three independent experiments. An asterisk indicates that the value is significantly different from IFNg-treated cells.
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Fig. 6. The effects of L-NAME, EGCG and FeTPPS on IFNg-mediated activation of proteasome in VL-17A cells. VL-17A cells were simultaneously treated
with IFNg and with 300 mM L-NAME (panel A), 200 mM EGCG (panel B) or 10 mM FeTPPS (panel C) for 24 hr, and proteasome activity was measured by
FLF-AFC hydrolysis. Data are from one experiment (quadruplicate measurements). Two other experiments (not shown) had similar results and similar
significant differences between IFNg-untreated controls and IFNg-treated cells. Mean values (SD) are shown from one experiment due to variability in
basal activities of proteasome in the three experiments. A: L-NAME-treated cells; B: EGCG-treated cells; C: FeTPPS-treated cells. Asterisk indicates
significant difference (P < 0:05) between IFNg-untreated controls (dark bars) vs. IFNg-treated cells (open bars).

ratio declined 6–7-fold in ethanol-treated VL-17A cells
after 1 hr of IFNg treatment. To further test whether STAT1
phosphorylation in VL-17A cells was affected by the
products of ethanol metabolism, we treated cells for
72 hr with both ethanol and 4-methylpyrazole (4MP), an
inhibitor of ethanol metabolism. Treatment with 4MP
prevented the ethanol-induced suppression of STAT1 phosphorylation in VL-17A cells (Fig. 10).

4. Discussion
The liver is routinely exposed to toxic agents, microbes
and viruses arriving via the portal vein from the gastrointestinal tract. Such exposure can activate liver immune
cells. Activated intrahepatic lymphocytes secrete IFNg
and other cytokines in response to these stimuli, thus
putting hepatocytes under continuous cytokine exposure.

N.A. Osna et al. / Biochemical Pharmacology 66 (2003) 697–710
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Fig. 7. The effects of IFNg and/or ethanol treatment on CYP2E1 activity in VL-17A cells. VL-17A cells were pre-treated or not with 100 mM ethanol (E100)
for 48 hr. IFNg was then added (10 ng/mL), and cells were incubated for an 24 additional hours. Data are mean values (SD) of five independent
experiments. Asterisk indicates significant difference (P < 0:05) between control values (untreated cells) and ethanol or IFNg treatments.

Hepatocytes abundantly express proteasome activity and
previous studies in vivo have shown that IFNg can regulate
this activity in liver tissue [36]. However, it is not clear
whether IFNg specifically affects proteasome activity in
hepatocytes or in intrahepatic immune cells in both. In this
investigation, using a liver-derived culture system, we
sought to determine whether IFNg altered proteasome
activity in cultured recombinant Hep G2 cells, which stably
express the ethanol-metabolizing enzymes, CYP2E1 and
ADH. Because liver cells are the primary sites of ethanol
oxidation, we also explored the possibility that any IFNg
modulation of proteasome activity as well as the transduction of IFNg signals in these cells may be altered by ethanol
or its metabolism.
In this study, IFNg enhanced proteasome chymotrypsinlike activity in recombinant Hep G2 cells. The kinetics of
this response showed an elevation in enzyme activity as early
as 4 hr and which remained elevated at the same level 24 hr
after exposure to the cytokine. These results indicate that the
IFNg-elicited enhancement in enzyme activity was probably
not the result of cytokine-induced de novo proteasome

synthesis, as the enzyme has a very slow rate of turnover
t1=2 ¼ 12–15 days in rat liver [37]. Rather, the rapidity of this
increase in response to IFNg treatment appeared to reflect
changes in the activity of the existing enzyme.
Enhancement of proteasome chymotryspin-like activity in
Hep G2-derived cells depended upon the expression of
CYP2E1 because only VL-17A cells (ADHþ/CYP2E1þ)
and E-47 cells (CYP2E1þ) showed this response to IFNg.
Additionally, the degree of IFNg-mediated activation of the
proteasomewas positively associated with the basal CYP2E1
activity in VL-17A cells. Furthermore, when we treated the
cells with IFNg in the presence of CYP2E1 inhibitor DAS,
IFNg no longer increased proteasome activity. Thus,
CYP2E1 catalysis was necessary for IFNg-mediated proteasome activation, leading us to suggest that one or more
products generated by CYP2E1 influence(s) proteasome
activity. It is well known that CYP2E1 is a loosely coupled
enzyme that can generate superoxide and other reactive
species even in the absence of substrate [38,39].
In addition to CYP2E1 catalysis, nitric oxide generation
was also required for proteasome activation by IFNg. This
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Fig. 8. The effects of tyrphostin AG 490 on IFNg-mediated effects on CYP2E1 and proteasome in VL-17A cells. Cells were treated or not with 1 mM
tyrphostin AG 490 for 1 hr. IFNg (10 ng/mL) was added, and cells were incubated for additional 24 hr. CYP2E1 activity (panel A) was assayed in microsome
fractions of cell lysates proteasome activity (panel B) assayed in situ by FLF-AFC hydrolysis. Because of intra-experimental variation in enzyme activity,
data are expressed as a percent of untreated control from three independent experiments. Statistical significance was assessed by a mixed effect ANOVA
model, in which pair wise comparisons were made among the various treatment groups. Asterisk indicates that the value is significantly different (P < 0:05)
from IFNg-treated cells.

was indicated by the blockage of IFNg-mediated proteasome activation by L-NAME and EGCG. Both these agents
inhibit NO formation. Furthermore, our time-course experiments (Fig. 1) indicated that proteasome activity began to
rise after 4 hr of IFNg treatment. This time period is consistent with that necessary for induction of iNOS by IFNg,
previously seen in macrophages [40]. Therefore, we propose
that VL-17A cells with higher basal CYP2E1 activities had a
greater capacity to produce superoxide from CYP2E1. NO,
that was generated by iNOS, following IFNg treatment
reacted with superoxide to form peroxynitrite, which, in
turn, increased proteasome activity. Furthermore, our results
showed that when VL-17A cells were exposed to the
peroxynitrite scavenger, FeTPPS, this agent also prevented
proteasome activation by the cytokine. These latter findings

further uphold our suggestion that the proximal agent
responsible for proteasome activation is peroxynitrite.
Peroxynitrite reacts with tyrosine residues in proteins,
forming nitrated proteins [41]. Previous studies have shown
that mild modification of the enzyme aconitase with low
concentrations of peroxynitrite inactivates this enzyme [42].
In light of these and similar findings [43] we thought it
unlikely that metabolically derived peroxynitrite would
activate the proteasome in VL-17A cells. To test this further,
we have recently conducted experiments in vitro, using
purified preparations of the 20S proteasome exposed to
low concentrations of the peroxynitrite donor 3-morpholinosydnonimine (SIN-1). Compared with untreated enzyme,
low SIN-1 concentrations enhanced proteasome chymotrypsin-like activity by as much as 2-fold. However, higher

N.A. Osna et al. / Biochemical Pharmacology 66 (2003) 697–710

707

Fig. 9. Effect of ethanol treatment on STAT1 phosphorylation in VL-17A and Hep G2 cells following exposure to IFNg. Cells were treated or not with
100 mM ethanol for 72 hr in serum-free DMEM or left untreated. During the final 24 hr of ethanol exposure cells were treated or not with IFNg (10 ng/mL)
for 0, 1, 5, 24 hr. Cell lysates were subjected to SDS–PAGE/Western blotting (30 mg protein/well). Data shown from Western blot are from one representative
experiment (out of a total of three with similar results). Panels A and B: phosphorylated STAT1 (pSTAT1) levels after 0–24 hr stimulation with IFNg, in
ethanol pretreated and untreated VL-17A (panel A) and Hep G2 (panel B) cells. Panels C and D: total STAT1 levels (0–24 hr in VL-17A cells (panel C) and
Hep G2 cells (panel D) treated with IFNg, untreated vs. ethanol-treated). Panel E: pSTAT1/STAT1 ratios in VL-17A cells (mean  SD, three experiments)
Asterisk indicates that value is significant (P < 0:05) in ethanol-untreated cells vs. ethanol-treated. Panel F: pSTAT1/STAT1 ratio in Hep G2 cells
(mean  SD, three experiments).

concentrations of SIN-1 caused its inactivation.2 These
observations further support our view that peroxynitrite
can activate the same catalytic activity of the proteasome
that was measured in VL-17A cells, but that such activation
is limited and can eventually result in the loss of proteasome
activity when the levels of the oxidant become excessive.
In view of these latter observations, it is noteworthy that
after 24 hr of IFNg treatment, CYP2E1 activity went down.
This IFNg-dependent decrease in CYP2E1 activity confirms the results of earlier studies in hepatocytes showing
that IFNg decreases a number of P450 isoenzymes by
suppressing their mRNA levels, thereby decreasing their
intracellular content [35]. This decrease also occurs at least
partly via nitric oxide inhibition of CYP2E1 [44]. Thus, we
suggest that in VL-17A cells IFNg-enhances production of
2

Osna, unpublished results.

NO, which reacts with superoxide to form peroxynitrite.
The latter, which is produced at low concentrations, in turn
activates the proteasome. At the same time, NO suppresses
CYP2E1 catalysis thereby limiting the quantity of superoxide generated by CYP2E1 and thus limiting the degree of
proteasome activation.
Proteasome activity declined after treatment of cells
with 100 mM ethanol. These results confirm our previous
results reported recently and can be attributed to ethanol
metabolism, since ethanol-elcited proteasome inactivation
can be prevented by inhibition of ethanol metabolism (see
Footnote 1). We do not know the mechanism responsible
for the decline in proteasome activity, but we speculate
that the induced levels of CYP2E1 may generate higher
levels of oxidants that contribute to proteasome inactivation. One of these oxidants may indeed be peroxynitrite, as
Baraona et al. recently demonstrated that chronic ethanol
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Fig. 10. Effects of ethanol with or without 4-methylpyrazole (4-MP) on STAT1 phosphorylation in VL-17A and Hep G2 cells. Cells were treated or not with
100 mM ethanol for 72 hr in the presence or absence of 5 mM 4-MP and then exposed to IFNg for 1 hr. Data are representative from one of two experiments.
Phosphorylated STAT1 (pSTAT1) in VL-17A cells (panel A) and Hep G2 cells (panel C) treated as indicated. Total STAT1 in VL-17A cells (panel B) and Hep
G2 cells (panel D) treated as indicated. The pSTAT1/STAT1 ratios are presented in panel E (VL-17A cells) and panel F (Hep G2 cells) as mean values of three
experiments. Asterisk indicates a significant difference (P < 0:05) in pSTAT1/STAT1 ratio between control and ethanol-treated cells, both exposed to IFNg.
Asterisks indicate a significant difference (P < 0:05) in pSTAT1/STAT1 ratio between 4MP-treated and -untreated cells exposed to ethanol and IFNg.

administration enhances iNOS activity and the formation
of peroxynitrite in rat liver [45].
When cells were exposed to ethanol, neither CYP2E1,
nor the proteasome was affected by IFNg. These results
indicated that IFNg-mediated effects on CYP2E1 catalysis
and proteasome activity were modulated via the same
signal transduction pathway. This conclusion is supported
by the observed prevention by tyrphostin AG 490 of IFNgmediated proteasome activation and decreased CYP2E1
activity. The results lead us to suggest that the regulation of
these enzymes is downstream from JAK-STAT1 signaling.
Exposure of VL-17A cells to 100 mM ethanol prior
to IFNg treatment prevented STAT1 phosphorylation in
ethanol-metabolizing VL-17A cells. Nguyen et al. [46]

reported an impaired IFNg-activated phosphorylation of
STAT1 after acute ethanol (30 min) treatment of hepatocytes. However, these authors found no alteration in STAT1
phosphorylation in ethanol-treated Hep G2 or in ADHþ
VA-13 cells [47]. They concluded that ethanol-induced
suppression of STAT1 phosphorylation could not be attributed to ethanol metabolism. In contrast, our results indicated that during ethanol exposure, VL-17A cells, but not
Hep G2 cells exhibited a prominent decrease in STAT1
phosphorylation. Furthermore, the prevention of ethanol
metabolism by treatment with 4-MP blocked the ethanolelicited reduction of STAT1 phosphorylation. Thus, we
conclude that one or more products of ethanol metabolism blocks IFNg signal transduction in VL-17A cells.
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Fig. 11. Hypothetical scheme depicting IFNg-mediated activation of proteasome in recombinant Hep G2 cells. IFNg binds to IFNgR and initiates JAKSTAT1 signal transduction. iNOS is activated via JAK-STAT1 pathway to catalyze NO formation. CYP2E1 catalyzes superoxide formation. The reaction
product of NO and superoxide, peroxynitrite, at low physiological concentrations activates the proteasome. In the presence of ethanol CYP2E1 activity is
increased, but ethanol metabolites prevent STAT1 phosphorylation, which blocks IFNg signal transduction. Thus, proteasome is not activated by IFNg in
ethanol-treated CYP2E1-expressing cells.

Currently, the identity of those inhibitory products is not
clear. In preliminary experiments (not shown) we have
observed that ethanol prevents STAT1 phosphorylation in
VA-13 cells, but not in E-47 cells, indicating that acetaldehyde has a role in blocking STAT1 phosphorylation. When
incubated in the presence of 100 mM ethanol, VL-17A cells
generate >200 mM acetaldehyde in the medium.3 Acetaldehyde is known to activate the protein kinase C (PKC)
pathway [48], which, in turn, down-regulates JAK-STATs
[47]. It was recently demonstrated that malondialdehyde–
acetaldehyde–protein (MAA) adducts also activate the PKC
pathway [49]. The formation of these secondary ethanolderived products may also contribute to the ethanol-induced
blockade of STAT1 phosphorylation. Thus, these and other
mechanisms remain to be investigated.
In Fig. 11, we present a proposed mechanism of proteasome activation in response to IFNg and how this response
may be regulated by ethanol.
In summary, our findings indicate that enhancement of
proteasome activity occurred in IFNg-treated Hep G2 cells
that express CYP2E1. This enhancement may be related to
the production of peroxynitrite, generated by CYP2E1catalysis (O2) and the iNOS activity (NO). Both proteasome activity and CYP2E1 activity are regulated by IFNg
via the JAK-STAT1 pathway. Ethanol metabolism prevents
phosphorylation of STAT1 making the proteasome in VL17A cells unresponsive to IFNg-mediated effects.
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